CERO · Cero Therapeutics Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $2.34M | - | $2.39M | $2.75M | $2.91M | - | $1.77M | $1.19M | $1.80M | - |
| SG&A | $2.51M | - | $1.98M | $1.97M | $2.04M | - | $2.63M | $2.43M | - | - |
| Total Operating Expenses | $4.85M | - | $4.36M | $4.72M | $4.95M | - | $1.54M | $2.41M | - | - |
| D&A | - | - | $69.4K | $76.3K | $76.3K | - | $115.4K | $115.4K | $115.4K | - |
| Operating Income | ($4.85M) | - | ($4.36M) | ($4.72M) | ($4.95M) | - | ($4.40M) | ($5.15M) | ($2.44M) | - |
| Interest Expense | $166.3K | - | - | - | - | - | ($157) | ($59.4K) | ($16) | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($5.89M) | - | ($4.86M) | ($5.42M) | ($5.11M) | - | ($4.23M) | ($2.45M) | - | - |
| EPS - Basic | ($0.20) | - | ($9.10) | ($61.71) | ($31.80) | - | ($180.00) | ($300.00) | ($540.00) | - |
| EPS - Diluted | ($0.20) | - | ($9.10) | ($61.71) | ($31.80) | - | ($180.00) | ($300.00) | ($540.00) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $857.5K | $1.66M | $1.90M | $3.20M | $5.10M | $3.33M | $3.38M | $3.65M | $4.59M | $96.9K |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $7.69M | $7.58M | $7.08M | $6.21M | $6.38M | $4.51M | $6.67M | $6.35M | $1.67M | - |
| Current Assets | $1.57M | $2.73M | $2.55M | $4.25M | $5.77M | $3.71M | $3.71M | $4.25M | $5.50M | - |
| Total Assets | $2.21M | $3.64M | $3.91M | $6.20M | $7.99M | $6.21M | $6.49M | $7.37M | $9.05M | $8.56M |
| Current Liabilities | $11.33M | $9.09M | $8.45M | $7.62M | $7.86M | $7.40M | $9.42M | $8.78M | $11.65M | $5.17M |
| Long-term Debt | $136.8K | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $11.46M | $9.09M | $8.45M | $7.84M | $8.32M | $8.10M | $10.19M | $9.85M | $13.03M | $14.32M |
| Stockholders' Equity | ($9.26M) | ($5.45M) | ($4.54M) | ($1.63M) | ($329.4K) | ($1.89M) | ($3.70M) | ($2.48M) | ($2.35M) | ($14.20M) |
| Retained Earnings | ($96.72M) | ($90.84M) | ($86.30M) | ($81.44M) | ($76.02M) | ($70.92M) | ($71.59M) | ($67.36M) | ($64.91M) | ($14.20M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $2.80M | - | - | - | - | - | - | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -266.9% | - | -124.2% | -87.3% | -63.9% | - | -65.1% | -33.2% | - | - |
| Return on equity | 63.6% | - | 106.9% | 331.6% | 1550.1% | - | 114.2% | 98.7% | - | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.14 | 0.30 | 0.30 | 0.56 | 0.73 | 0.50 | 0.39 | 0.48 | 0.47 | - |
| Quick ratio | 0.14 | 0.30 | 0.30 | 0.56 | 0.73 | 0.50 | 0.39 | 0.48 | 0.47 | - |
| Cash ratio | 0.08 | 0.18 | 0.22 | 0.42 | 0.65 | 0.45 | 0.36 | 0.42 | 0.39 | 0.02 |
| Leverage | ||||||||||
| Debt / Equity | -0.01 | - | - | - | - | - | - | - | - | - |
| Debt / Assets | 0.06 | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -29.1x | - | - | - | - | - | 28039.7x | 86.6x | 152396.6x | - |
| Equity multiplier | -0.24 | -0.67 | -0.86 | -3.80 | -24.26 | -3.28 | -1.75 | -2.97 | -3.86 | -0.60 |
| Liabilities / Assets | 5.20 | 2.50 | 2.16 | 1.26 | 1.04 | 1.31 | 1.57 | 1.34 | 1.44 | 1.67 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 2.1% | - | 0.9% | 8.2% | -103.0% | - | -924.3% | -1267.1% | - | - |
| Net income growth (YoY) | -15.3% | - | -14.9% | -121.2% | - | - | -1165.8% | -70.3% | - | - |
| EPS growth (YoY) | 99.4% | - | 94.9% | 79.4% | 94.1% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -2710.9% | -187.5% | -22.7% | 34.2% | 86.0% | 86.7% | 73.1% | 81.3% | 79.7% | -32.0% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing CERO THERAPEUTICS HOLDINGS against the 5 most active filers in the same SIC group.